Clinical Trials in Boston

Showing 1261-1280 of 17,836 trials

Revumenib in Combination With 7+3 + Midostaurin in AML

NCT06313437

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). The names of the study drugs involved in this study are: * Revumenib (SNDX-5613) (a type of menin inhibitor) * Midostaurin (a type of multi-kinase including FLT3 inhibitor) * Cytarabine (a type of antineoplastic agent) * Daunorubicin (a type of antineoplastic agent)

Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more

Richard Stone, MD22 participantsStarted Dec 2024

New Haven, Connecticut, United States • Boston, Massachusetts, United States

COMPLETEDPhase 2< 1 mile

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

NCT04484142

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.

Non-small Cell Lung Cancer

Daiichi Sankyo137 participantsStarted Mar 2021

Phoenix, Arizona, United States • La Jolla, California, United States • Santa Monica, California, United States +81 more locations

Revumenib in Combination With 7+3 + Midostaurin in AML

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Find Trials by Condition in Boston

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Evaluation of Safety and Efficacy of Micro-coring Device for Treatment of Facial Wrinkles and Skin Laxity

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding